A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza (R)) in patients with chronic myelomonocytic leukemia

作者:Tantravahi Srinivas K; Szankasi Philippe; Khorashad Jamshid S; Dao Kim Hien; Kovacsovics Tibor; Kelley Todd W; Deininger Michael W*
来源:Leukemia and Lymphoma, 2016, 57(10): 2441-2444.
DOI:10.3109/10428194.2016.1138295